Aashreya Ravichandra

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Inhibition of the ZEB1-BCL2 axis in cancer-associated fibroblasts as a strategy to improve chemotherapy response in intrahepatic cholangiocarcinoma.

Inhibition of the ZEB1-BCL2 axis in cancer-associated fibroblasts as a strategy to improve chemotherapy response in intrahepatic cholangiocarcinoma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: December 17, 2025

NADPH oxidase 1/4 dual inhibition impairs transforming growth factor-beta protumorigenic effects in cholangiocarcinoma cancer-associated fibroblasts.

NADPH oxidase 1/4 dual inhibition impairs transforming growth factor-beta protumorigenic effects in cholangiocarcinoma cancer-associated fibroblasts.

Journal: Signal transduction and targeted therapy

Published: September 02, 2024

Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma.

Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma.

Journal: Nature biomedical engineering

Published: March 01, 2023

Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma progression and therapeutic resistance.

Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma progression and therapeutic resistance.

Journal: Advances in cancer research

Published: August 12, 2022

Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma.

Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma.

Journal: Hepatology (Baltimore, Md.)

Published: June 23, 2022

The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver.

The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver.

Journal: Science translational medicine

Published: April 06, 2022

Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations.

Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations.

Journal: Cancer cell

Published: June 15, 2021

Mouse Models of Liver Fibrosis.

Mouse Models of Liver Fibrosis.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: May 24, 2021

Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis.

Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis.

Journal: Nature

Published: April 26, 2021

Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts.

Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts.

Journal: The Journal of clinical investigation

Published: December 23, 2020

Chimeric Antigen Receptor T Cells as Senolytic and Antifibrotic Therapy.

Chimeric Antigen Receptor T Cells as Senolytic and Antifibrotic Therapy.

Journal: Hepatology (Baltimore, Md.)

Published: October 15, 2020

Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations.

Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations.

Journal: Cancer cell

Published: July 30, 2020

Showing 1-12 of 13

Last Updated: 09/26/2026